Oncotalks | Powered by Novartis

Prof. Jacob Schachter, MD, PhD

ASCO , Hungary
Share this item

Prof. Jacob Schachter, MD, PhD from the Sheba Medical Center, Tel Hashomer is commenting on abstracts in the field of melanoma presented at ASCO 2019 in Chicago

Related items

ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)

ASCO , Latvia , Lithuania , Estonia , Hungary , Albania

00:10:57

ASCO 2019 Rafael Villanueva, MD

ASCO 2019 Rafael Villanueva, MD

Rafael Villanueva, MD from the Institut Català d'Oncologia, Barcelona, Spain is commenting on his abstract that has been presented at ASCO 2019 in Chicago. Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)

ASCO , Kisqali Channel , Lithuania , Hungary , Albania

00:04:01

ASCO 2019 Martin Bögemann

ASCO 2019 Martin Bögemann

Martin Bögemann from the Universitätsklinikum Münster, Duitsland is commenting on "Boegemann M. et al. Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. J Clin Oncol 37, 2019 (suppl; abstr 4574)", which her presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:02:46

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:06:31

ASCO 2019 Ana Arance, MD, PhD

ASCO 2019 Ana Arance, MD, PhD

Ana Arance, MD, PhD from the Hospital Clínic de Barcelona is commenting on Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507), which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:02:14

ASCO 2019 Dr. Razvan Curca

ASCO 2019 Dr. Razvan Curca

Dr. Razvan Curca from the Spitalul Judetean de Urgenta, Alba Iulia is commenting on two publications presented at ASCO 2019 in ChicagoNathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)TAF-ADV-2-06.2019

ASCO , Lithuania , Hungary , Albania

00:08:53